OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results
Opko Health, Inc. (OPK)
Last opko health, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.opko.com
Company Research
Source: GlobeNewswire
MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth quarter of 2024 and recent weeks include the following: Enrollment and dosing underway by Merck in the Phase 1 Epstein-Barr virus (EBV) vaccine trial. Dosing of patients has commenced for the Phase I study (NCT06655324) of an EBV vaccine candidate being developed in collaboration with Merck. The investigational vaccine, based on ModeX’s ferritin nanoparticle vaccine platform, is being evaluated for safety and tolerability in up to 200 healthy adults. Commencement of this study triggered a milestone payment to ModeX.Awarded $51 million of additional funding under an existing BARDA contract to develop COVID multispecific antibodies and to initiate an influenza program. ModeX Therapeutics was awarded $26.9 million of new funding under an existing contract with the Biomedical Advan
Show less
Read more
Impact Snapshot
Event Time:
OPK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPK alerts
High impacting Opko Health, Inc. news events
Weekly update
A roundup of the hottest topics
OPK
News
- JAMA (Journal of the American Medical Association) Recognizes GUARDIAN Newborn Genomic Screening Study Among Its Research of the Year [Yahoo! Finance]Yahoo! Finance
- The Bull Case For OPKO Health (OPK) Could Change Following CEO Frost's Major Share Purchase Amid Downgrade [Yahoo! Finance]Yahoo! Finance
- OPKO Health (NASDAQ:OPK) is now covered by analysts at JPMorgan Chase & Co.. They set a "neutral" rating on the stock.MarketBeat
- OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Guggenheim Reaffirmed Buy on GeneDx at October End, Lifted Price Target to $170 After Q3 Beat [Yahoo! Finance]Yahoo! Finance
OPK
Earnings
- 10/29/25 - Beat
OPK
Sec Filings
- 11/21/25 - Form 4
- 11/20/25 - Form 4
- 11/19/25 - Form 4
- OPK's page on the SEC website